Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts

被引:0
作者
Emilie Normand
Anita Franco
Alain Moreau
Valérie Marcil
机构
[1] Research Center of the Sainte-Justine University Hospital,Department of Nutrition, Faculty of Medicine
[2] Université de Montreal,Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases
[3] Research Center of the Sainte-Justine University Hospital,Department of Biochemistry and Molecular Medicine, Faculty of Medicine
[4] Université de Montreal,Department of Stomatology, Faculty of Dentistry
[5] Université de Montréal,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
It has been proposed that girls with adolescent idiopathic scoliosis (AIS) tend to have a taller stature and a lower body mass index. Energy homeostasis, that is known to affect bone growth, could contribute to these characteristics. In circulation, dipeptidyl peptidase-4 (DPP-4) inactivates glucagon-like peptide-1 (GLP-1), an incretin that promotes insulin secretion and sensitivity. Our objectives were to investigate DPP-4 status in plasma and in osteoblasts of AIS subjects and controls and to evaluate the regulatory role of metabolic effectors on DPP-4 expression. DPP-4 activity was assessed in plasma of 113 girls and 62 age-matched controls. Osteoblasts were isolated from bone specimens of AIS patients and controls. Human cells were incubated with glucose, insulin, GLP-1 and butyrate. Gene and protein expressions were evaluated by RT-qPCR and Western blot. Our results showed 14% inferior plasma DPP-4 activity in AIS patients when compared to healthy controls (P = 0.0357). Similarly, osteoblasts derived from AIS subjects had lower DPP-4 gene and protein expression than controls by 90.5% and 57.1% respectively (P < 0.009). DPP-4 expression was regulated in a different manner in osteoblasts isolated from AIS participants compared to controls. Our results suggest a role for incretins in AIS development and severity.
引用
收藏
相关论文
共 50 条
[41]   Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism [J].
Trzaskalski, Natasha A. ;
Fadzeyeva, Evgenia ;
Mulvihill, Erin E. .
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2020, 13
[42]   Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System [J].
B. Solun ;
D. Marcoviciu ;
D. Dicker .
Current Cardiology Reports, 2013, 15
[43]   Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection [J].
Marina Rankovic ;
Nevena Jeremic ;
Ivan Srejovic ;
Katarina Radonjic ;
Aleksandra Stojanovic ;
Milos Glisic ;
Stefani Bolevich ;
Sergey Bolevich ;
Vladimir Jakovljevic .
Heart Failure Reviews, 2021, 26 :437-450
[44]   Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas [J].
Deacon, C. F. ;
Lebovitz, H. E. .
DIABETES OBESITY & METABOLISM, 2016, 18 (04) :333-347
[46]   Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4 [J].
Mishra, Avinash ;
Cross, Megan ;
Hofmann, Andreas ;
Coster, Mark J. ;
Karim, Abdul ;
Sattar, Abdul .
JOURNAL OF COMPUTATIONAL BIOLOGY, 2019, 26 (12) :1470-1486
[47]   Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience [J].
Derosa, Giuseppe ;
Maffioli, Pamela .
DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (04) :350-364
[48]   Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences [J].
Baetta, Roberta ;
Corsini, Alberto .
DRUGS, 2011, 71 (11) :1441-1467
[49]   Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes [J].
Ahren, Bo .
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (04) :593-607
[50]   Development of a fluorogenic small substrate for dipeptidyl peptidase-4 [J].
Ogawa, Futa ;
Takeda, Masanori ;
Miyanaga, Kanae ;
Tani, Keita ;
Yamazawa, Ryuji ;
Ito, Kiyoshi ;
Tarui, Atsushi ;
Sato, Kazuyuki ;
Omote, Masaaki .
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2017, 13 :2690-2697